Neuroendocrine gastroenteropancreatic tumors
Showing 1 - 25 of >10,000
Gastroenteropancreatic Neuroendocrine Tumours
Recruiting
- Gastroenteropancreatic Neuroendocrine Tumor
- 68Ga-DOTATOC PET as a part of their clinical diagnostic work-up will be included
-
Milano, ItalyIrccs San Raffaele
Nov 24, 2023
Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine
Not yet recruiting
- Digestive System Neuroendocrine Tumor G1
- +5 more
- Tumor Debulking
- +5 more
-
Nashville, TennesseeVanderbilt University/Ingram Cancer Center
Aug 23, 2023
Neuroendocrine Tumors Trial in Beijing (Lutetium[177Lu] Oxodotreotide Injection)
Not yet recruiting
- Neuroendocrine Tumors
- Lutetium[177Lu] Oxodotreotide Injection
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
May 30, 2023
Neuroendocrine Tumors, Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors Trial in New York (177Lu-DOTATATE)
Recruiting
- Neuroendocrine Tumors
- Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jan 19, 2023
Advanced Gastroenteropancreatic Neuroendocrine Tumor Trial (68Ga-DOTATOC)
Not yet recruiting
- Advanced Gastroenteropancreatic Neuroendocrine Tumor
- (no location specified)
Oct 16, 2023
Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Trial in Cleveland (TQ Formula (black
Not yet recruiting
- Gastroenteropancreatic Neuroendocrine Tumor
- Gastroenteropancreatic Neuroendocrine Neoplasm
- TQ Formula (black seed oil capsules)
- +2 more
-
Cleveland, OhioUniversity hospitals Seidman Cancer Center, Case Comprehensive C
Aug 12, 2022
Advanced Gastroenteropancreatic Neuroendocrine Tumor Trial (Lutetium (177Lu) Oxodotreotide Injection;long-acting Octreotide,
Not yet recruiting
- Advanced Gastroenteropancreatic Neuroendocrine Tumor
- Lutetium (177Lu) Oxodotreotide Injection;long-acting Octreotide
- long-acting Octreotide.
- (no location specified)
May 22, 2023
Gastroenteropancreatic Neuroendocrine Tumors Trial in Marseille ([68Ga]-DOTANOC PET/CT)
Completed
- Gastroenteropancreatic Neuroendocrine Tumors
- [68Ga]-DOTANOC PET/CT
-
Marseille, FranceAP-HM
Oct 12, 2022
Neuroendocrine Tumors Trial in Toronto (F18-FDG)
Recruiting
- Neuroendocrine Tumors
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
May 20, 2022
Patients With Gastroenteropancreatic Neuroendocrine Tumors Trial in France (68-Ga-DOTANOC)
Completed
- Patients With Gastroenteropancreatic Neuroendocrine Tumors
-
Angers, France
- +4 more
Jan 6, 2022
Neuroendocrine Carcinoma Trial in France (Nivolumab, Ipilimumab)
Active, not recruiting
- Neuroendocrine Carcinoma
-
Aix-en-Provence, France
- +6 more
Mar 9, 2022
Gastroenteropancreatic Neuroendocrine Tumor Trial in Stanford (Lutathera, Gallium 68 Dotatate, Computed Tomography (CT))
Suspended
- Gastroenteropancreatic Neuroendocrine Tumor
- Lutathera
- +4 more
-
Stanford, CaliforniaStanford Cancer Institute Palo Alto
Sep 21, 2022
Neuroendocrine Tumors Trial in Belgium (Liquid biopsies, Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT))
Recruiting
- Neuroendocrine Tumors
- Liquid biopsies
- Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)
-
Bornem, Antwerp, Belgium
- +7 more
Jun 1, 2022
Neuroendocrine Tumors Trial in Edegem, Sint-Niklaas, Nicosia (Liquid biopsies, Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT))
Recruiting
- Neuroendocrine Tumors
- Liquid biopsies
- Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)
-
Edegem, Antwerp, Belgium
- +2 more
Feb 24, 2022
Lutathera® in Somatostatin Receptor Positive
Recruiting
- Somatostatin Receptor-positive GEP-NET
- Lutathera
-
Seongnam Si, Gyeonggi Do, Korea, Republic of
- +4 more
Jun 29, 2022
Nutrition in Gastroenteropancreatic Neuroendocrine Tumor
Active, not recruiting
- Gastroenteropancreatic Neuroendocrine Tumor
-
El Palmar, Murcia, Spain
- +15 more
Feb 16, 2022
Neuroendocrine Tumors,Gastroenteropancreatic Trial in Taipei (Cabozantinib, Lanreotide)
Not yet recruiting
- Neuroendocrine Tumors,Gastroenteropancreatic
-
Taipei, TaiwanNational Taiwan University Hospital
Sep 9, 2021
Assay asBiomarker for Gastroenteropancreatic and Lung
Completed
- Gastroenteropancreatic Neuroendocrine Tumor
- Lung Neuroendocrine Neoplasm
- NETest
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Aug 3, 2021
Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST) Trial in Boston, Madrid, Sevilla (Lurbinectedin,
Recruiting
- Advanced Solid Tumors
- +11 more
-
Boston, Massachusetts
- +4 more
Dec 12, 2022
Financial Toxicity and Patient-Reported Outcomes in GEP-NEN
Recruiting
- Neuroendocrine Tumors
-
Milan, ItalyIRCCS Ospedale San Raffaele
Apr 16, 2022
Neuroendocrine Tumors Trial in Seoul (Lanreotide autogel)
Recruiting
- Neuroendocrine Tumors
- Lanreotide autogel
-
Seoul, Korea, Republic ofChanghoon Yoo
Jul 18, 2022
Neuroendocrine Tumor, Gastroenteropancreatic Trial in Milano (Surgery)
Active, not recruiting
- Neuroendocrine Tumor
- Gastroenteropancreatic
- Surgery
-
Milano, ItalySan Raffaele Hospital IRCCS
May 5, 2022
Neuroendocrine Tumors, Carcinoid Tumor, Pulmonary Carcinoid Tumor Trial in Vancouver (177Lu-DOTATOC)
Not yet recruiting
- Neuroendocrine Tumors
- +6 more
-
Vancouver, British Columbia, CanadaBC Cancer
Aug 19, 2022